王芳芳, 白宝宝, 周海佳, 马文帅, 李妍. 药物涂层球囊在急性ST段抬高型心肌梗死介入治疗中安全性和有效性[J]. 心脏杂志, 2020, 32(3): 244-247. DOI: 10.12125/j.chj.202004002
    引用本文: 王芳芳, 白宝宝, 周海佳, 马文帅, 李妍. 药物涂层球囊在急性ST段抬高型心肌梗死介入治疗中安全性和有效性[J]. 心脏杂志, 2020, 32(3): 244-247. DOI: 10.12125/j.chj.202004002
    Fang-fang WANG, Bao-bao BAI, Hai-jia ZHOU, Wen-shuai MA, Yan LI. Safety and efficacy of drug coated balloon in patients with acute ST-segment elevation myocardial infarction (STEMI) during percutaneous coronary intervention (PCI)[J]. Chinese Heart Journal, 2020, 32(3): 244-247. DOI: 10.12125/j.chj.202004002
    Citation: Fang-fang WANG, Bao-bao BAI, Hai-jia ZHOU, Wen-shuai MA, Yan LI. Safety and efficacy of drug coated balloon in patients with acute ST-segment elevation myocardial infarction (STEMI) during percutaneous coronary intervention (PCI)[J]. Chinese Heart Journal, 2020, 32(3): 244-247. DOI: 10.12125/j.chj.202004002

    药物涂层球囊在急性ST段抬高型心肌梗死介入治疗中安全性和有效性

    Safety and efficacy of drug coated balloon in patients with acute ST-segment elevation myocardial infarction (STEMI) during percutaneous coronary intervention (PCI)

    • 摘要:
        目的  观察急性ST段抬高型心肌梗死(STEMI)患者行经皮冠状动脉介入(PCI)术时,应用药物涂层球囊治疗的安全性和有效性。
        方法  选取2018年(9~12)月共80例因STEMI就诊于我科的患者,将受试对象随机分为药物涂层球囊治疗组(球囊组,n=38)和药物洗脱支架(DES)治疗组(支架组,n=42)。术后常规随访1年,了解术后1个月、6个月和1年的心脏彩超左心功能、主要不良心血管事件(MACEs)发生率,术后1年时复查冠脉造影了解两组晚期管腔丢失(LLL)情况。
        结果  术后6个月和1年随访时,两组心脏彩超左室射血分数(LVEF)和左室舒张末期内径(LVEDD)均较住院期间有所改善(P<0.05),两组之间比较差异无统计学意义。球囊组靶病变LLL为(−0.12±0.46)mm,而支架组靶病变LLL为(0.14±0.37)mm(P<0.05)。1年内球囊组MACEs发生率为11%,支架组MACEs事件发生率12%,两组比较差异无统计学意义。
        结论  STEMI行PCI治疗时单纯DCB治疗是安全有效的,并且在1年随访期内显示出良好的临床结果。

       

      Abstract:
        AIM  To investigate the safety and efficacy of drug coated balloon (DCB) in patients with acute ST-segment elevation myocardial infarction (STEMI) during percutaneous coronary intervention (PCI).
        METHODS  Eighty STEMI patients in our department from September 2018 to December 2018 were enrolled and divided into DCB group (n=38) and drug-eluting stents group (DES). The patients were followed up for one year and their chocardiography and major adverse cardiac events (MACEs) were collected at 1 month, 6 months and 1 year after operation. Late lumen loss (LLL) was examined during coronary angiography at 1 year after operation.
        RESULTS  At the follow-up of 6 months and 1 year after operation, the left ventricular ejection fraction (LVEF) and the left ventricular end diastolic diameter (LVEDD) in two groups were all improved compared with those during hospitalization. The difference was statistically significant (P<0.05) and there was no statistically significant difference between the two groups. The LLL in DCB group was (−0.12±0.46) mm and that in DES group was (0.14±0.37) mm, with statistically significant difference (P<0.05). The incidence of MACEs was 10.5% in DCB group and 11.9% in DES group, with no statistically significant difference between the two groups.
        CONCLUSION  DCB treatment is safe and effective in patients with STEMI during PCI and one-year follow-up shows good clinical and angiographic results.

       

    /

    返回文章
    返回